Document Type : Research articles


1 Department of Psychiatry, School of Medicine, Kashan University of Medical Science, Kashan, Iran

2 Department of Psychiatry, Kashan University of Medical Sciences, Kashan, Iran

3 Department of Community Medicine, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran


Background: Methamphetamine dependence is a growing global problem. Currently, there are no approved pharmacotherapy options for the management of methamphetamine dependence. One of the alternatives to manage this addiction is the use of N acetylcysteine (NAC) due to its capacity to restore homeostasis in the brain glutamate systems disrupted in addiction and its ability to reduce craving and the risk of relapse.
Methods: Methamphetamine-dependentvolunteersundermethadonetreatment(n= 38) wererandomizedtoreceivedailydosesof 1200 mg of NAC, or placebo. The participants were followed for 12 weeks (two visits weekly). Craving and Beck Inventory Depression (BDI) was determined at the beginning of the study and also after one month, two months, and three months. Addiction severity index (ASI) was recorded at the beginning of the study and after three months. The data were analyzed via SPSS version 16.0 (SPSS Inc. Chicago, Illinios, USA)
Results: The mean score of craving and BDI reduced after two months with NAC treatment. ASI (e.g., substance, familial, and psy- chiatric categories) was significantly reduced at the end of the study in the NAC group compared to placebo (P < 0.001). The success of the treatment in groups of NAC and placebo were 84% and 73%, respectively (P = 0.001). 63.2% of the NAC group patients avoided substance use for more than a month, but this was 10.5% in the placebo group (P = 0.001).
Conclusions: The NAC showed good efficacy in suppressing methamphetamine craving, addiction severity index, and depression. It may be a useful pharmacological treatment for methamphetamine dependency.


  1. Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. Drug Alcohol Depend. 2007;87(2-3):249-57. doi: 10.1016/j.drugalcdep.2006.08.026. [PubMed: 17182196]. [PubMed Central: PMC1904343].
  2. Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8(10). e76635. doi: 10.1371/journal.pone.0076635. [PubMed: 24204649]. [PubMed Central: PMC3811989].
  3. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci. 2002;22(9):3312-20. [PubMed: 11978805]. [PubMed Central: PMC6758398].
  4. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377-82. doi: 10.1176/appi.ajp.158.3.377. [PubMed: 11229977].
  5. Shearer J, Gowing LR. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev. 2004;23(2):203-11. doi: 10.1080/09595230410001704190. [PubMed: 15370027].
  6. Batki SL, Moon J, Bradley M, Hersh D, Smolar S, Mengis M, et al. Fluoxetine in methamphetamine dependence—a controlled trial: preliminary analysis. Problems of Drug Dependence. 1999.
  7. Shoptaw S, Huber A, Peck J, Yang X, Liu J, Jeff D, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(1):12-8. doi: 10.1016/j.drugalcdep.2006.03.005. [PubMed: 16621339].
  8. Galloway GP, Newmeyer J, Knapp T, Stalcup S, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. Journal of Substance Abuse Treatment. 1996;13(6):493-7. doi: 10.1016/s0740-5472(96)00154-7.
  9. Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(3):177-84. doi: 10.1016/j.drugalcdep.2006.03.019. [PubMed: 16740370].
  10. Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008;11(1):1-14. doi: 10.1017/S1461145707007778. [PubMed: 17470315].
  11. Cruickshank CC, Montebello ME, Dyer KR, Quigley A, Blaszczyk J, Tomkins S, et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008;27(3):326-33. doi: 10.1080/09595230801935672. [PubMed: 18368615].
  12. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat. 2008;35(3):334-42. doi: 10.1016/j.jsat.2007.12.003. [PubMed: 18329221].
  13. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract. 2011;24(6):541-50. doi: 10.1177/0897190011426557. [PubMed: 22095579].
  14. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15(1):105-10. doi: 10.1080/10550490500419169. [PubMed: 16449100]. [PubMed Central: PMC1513138].
  15. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756-63. doi: 10.1001/archgenpsychiatry.2009.60. [PubMed: 19581567].
  16. Sansone RA, Sansone LA. Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci. 2011;8(1):10-4. [PubMed: 21311702]. [PubMed Central: PMC3036554].
  17. Asevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. Braz J Psychiatry. 2014;36(2):168-75. doi: 10.1590/1516-4446-2013-1244. [PubMed: 24676047].
  18. Mousavi SG, Sharbafchi MR, Salehi M, Peykanpour M, Karimian Sichani N, Maracy M. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study. Arch Iran Med. 2015;18(1):28-33. [PubMed: 25556383].
  19. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory--Second edition: BDI-II-PERSIAN. Depress Anxiety. 2005;21(4):185-92. doi: 10.1002/da.20070. [PubMed: 16075452].
  20. Davoudi MR, Omidi A, Sehat M. Comparison of anxiety and depression symptoms between male daily smokers and nondaily smokers resident in Kashan city during 2016-2017. Feyz Journal of Kashan University of Medical Sciences. 2017;21(5):490-7.
  21. Ekhtiari H, Alam-Mehrjerdi Z, Nouri M, George S, Mokri A. Designing and evaluation of reliability and validity of visual cue-induced craving assessment task for methamphetamine smokers. Basic and Clinical Neuroscience. 2010;1(4):34-7.
  22. Wu TY, Lin CY, Arestedt K, Griffiths MD, Brostrom A, Pakpour AH. Psychometric validation of the Persian nine-item Internet Gaming Disorder Scale - Short Form: Does gender and hours spent online gaming affect the interpretations of item descriptions? J Behav Addict. 2017;6(2):256-63. doi: 10.1556/2006.6.2017.025. [PubMed: 28571474]. [PubMed Central: PMC5520122].
  23. McKetin R, Dean OM, Baker AL, Carter G, Turner A, Kelly PJ, et al. A potential role for N-acetylcysteine in the management of methamphetamine dependence. Drug Alcohol Rev. 2017;36(2):153-9. doi: 10.1111/dar.12414. [PubMed: 27241765].